Amyloidosis Clinical Trials

The amyloidosis clinical trials team is interested in seeing how exciting new amyloidosis drugs can help to improve the outcomes and quality of life for those living with amyloidosis.

Feel free to call or e-mail the Knight Cardiovascular Institute research team at 503-418-1964 or by emailing heartresearch@ohsu.edu. You will then be forwarded to the appropriate research team member who will be able to see if you qualify for any of the clinical trials being offered at OHSU. 

You can also find all the of heart failure clinical trials, that are currently enrolling patients, below. 

EIDOS AG10-201

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokintecs and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy.

Primary investigator:

Stephen Heitner, M.D.

Sub-investigators:

Protocol number:

IRB00018169

Study purpose:

The primary objective of this study is to evaluate the safety and tolerability of AG10 administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM).

Contact:

Grace Van Ness (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu